Emily Li

Years Active: 2020-2020
Publications (10 Years): 1

This page only lists publications with an associated author ORCID identifier.

Publications

Preeti Narayan, Tatiana M Prowell, Jennifer J Gao, Laura L Fernandes, Emily Li, Xiling Jiang, Junshan Qiu, Jianghong Fan, Pengfei Song, Jingyu Yu, Xinyuan Zhang, Bellinda L King-Kallimanis, Wei Chen, Tiffany K Ricks, Yutao Gong, Xing Wang, Katherine Windsor, Steve Y Rhieu, Gerlie Geiser, Anamitro Banerjee, Xiaohong Chen, Francisca Reyes Turcu, Deb K Chatterjee, Anand Pathak, Jeffrey Seidman, Soma Ghosh, Reena Philip, Kirsten B Goldberg, Paul G Kluetz, Shenghui Tang, Laleh Amiri-Kordestani, Marc R Theoret, Richard Pazdur, Julia A Beaver
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (7) (2020)

Emily Li.css-eqlu8i{font-size:small;padding-left:4px;}